Therapy of renal anemia with recombinant human erythropoietin in children with end-stage renal disease.
Scigalla
P
P
Boehringer Mannheim GmbH, Department of Clinical Research, Mannheim, FRG.
Bonzel
K E
KE
Bulla
M
M
Burghard
R
R
Dippel
J
J
Geisert
J
J
Leumann
E
E
von Lilien
T
T
Müller-Wiefel
D E
DE
Offner
G
G
D000293:Adolescent; D000328:Adult; D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D002648:Child; D002675:Child, Preschool; D004906:Erythrocyte Count; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005293:Ferritins / Q000378:metabolism; D006128:Growth / Q000187:drug effects; D006400:Hematocrit; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications*; D008297:Male; D015337:Multicenter Studies as Topic; D012156:Reticulocytes; D012640:Seizures / Q000139:chemically induced; D013927:Thrombosis / Q000139:chemically induced
D004921:Erythropoietin; D005293:Ferritins